Mitoguazone

Summary

Mitoguazone (CHEMBL216913) is a phase-3 clinical-stage small-molecule antineoplastic agent (ATC L01XX16); indicated across 2 conditions including neoplasm and lymphoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: L01XX16
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 184.2 Da · C5H12N8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL216913
Name	Mitoguazone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5351154
ChEBI	CHEBI:43996
ATC	L01XX16
Molecular formula	C5H12N8
Molecular weight	184.2
InChIKey	MXWHMTNPTTVWDM-NXOFHUPFSA-N

SMILES: C/C(=N\N=C(N)N)/C=N/N=C(N)N

IUPAC name: 2-[(E)-[(1E)-1-(diaminomethylidenehydrazinylidene)propan-2-ylidene]amino]guanidine

ChEBI definition: A hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine.

Pharmacological roles (ChEBI): antineoplastic agent, apoptosis inducer, EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor.

Also known as: Mitoguazona, Mitoguazone, methylglyoxalbisguanylhydrazone, Methylglyoxalbis(guanylhydrazone), MITOGUAZONE, Methylglyoxal bis(guanylhydrazone)

Parent form; salt/anhydrous children: CHEMBL1995011

Patent coverage: 8,895 distinct patent families (38,307 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 37,986 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: S-adenosylmethionine decarboxylase proenzyme, Diamine oxidase [copper-containing].

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P17708	6	IC50	1000	nM	CHEMBL_ACT_179239
P36633	5.82	IC50	1500	nM	CHEMBL_ACT_179240

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
lymphoma	3	MONDO:0005062	EFO:0000574

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00920153	PHASE3	TERMINATED	Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
NCT00002348	PHASE2	COMPLETED	A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin’s Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).